“We are excited about our upcoming milestones, including the opportunity to share new clinical data from the FIREFLY-1 trial in an oral presentation at ASCO,” CEO Jeremy Bender said in a statement.ĭay One’s net loss was $42.4 million in the quarter, with a non-cash stock compensation expense of $9.4 million, compared to $27.7 million with a non-cash stock compensation expense of $6.2 million a year earlier. Whats Happening With Day One Biopharmaceuticals Inc Stock Today Day One Biopharmaceuticals Inc (DAWN) stock is down -1. The uptick was due to additional employee compensation costs, as well as clinical trial and pre-commercial manufacturing activities related to the company’s lead brain tumor treatment candidate, tovorafenib. Research and development costs were $27.8 million, compared to $15 million in the same period of 2022. Popular Careers with Day One Biopharmaceuticals Job Seekers Clinical Data Manager Career HRIS Analyst Career Operations Manager Career Project Manager. South San Francisco, California, United States 101-250 Post-IPO Equity Public / 7,892 Highlights Stock Symbol NASDAQ:DAWN Total Funding Amount 362. Day One Biopharmaceuticals is a differentiated company created to find and develop new therapies that meet the needs of people with cancer of all ages, starting with the biology of childhood cancer. Their latest funding was raised on from a Post-IPO Equity round. Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages. Data show an overall response rate (ORR) of 64 and clinical benefit rate (CBR) of 91 in the first 22 evaluable patients treated. The Brisbane, California company reported a cash position of $318.2 million as of March 31, which management believes is sufficient to fund operations into 2025. Day One Biopharmaceuticals has raised a total of 362.5M in funding over 3 rounds. J17:00 ET Source: Day One Biopharmaceuticals, Inc. Day One Biopharmaceuticals stock added more than 16% Monday afternoon after the company posted its first-quarter financial results.
0 Comments
Leave a Reply. |